secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001549595-24-000138
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix appoints drug commercialization veteran Anil Kapur to board of directors
------------------------------------------------------------------------------

- Appointed Anil Kapur as Class I director effective Oct 15, 2024, with term expiring at 2027 annual meeting.
- Mr. Kapur brings 25+ years of pharma exec experience, including launching Imbruvica and Darzalex.
- Received initial stock option for 50,000 shares vesting monthly over 3 years, plus annual equity awards.
- Appointment aims to support plan to advance NX-5948 into pivotal testing in 2025 and prepare for commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000138/0001549595-24-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000138/nrix-20241015.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer